基于双模态超声与分子数据的深度学习模型预测乳腺癌新辅助化疗反应
前瞻性纳入255例接受新辅助化疗的乳腺癌患者,基于治疗前B型超声和剪切波弹性成像构建影像组学与卷积神经网络模型。剪切波弹性成像预测反应优于B型超声,卷积神经网络优于影像组学;联合双模态超声与分子数据的卷积神经网络模型准确率83.60%±2.63%、敏感度87.76%±6.44%、特异度77.45%±4.38%。
要点
- 治疗前剪切波弹性成像预测新辅助化疗反应优于B型超声(P<0.001)。
- 卷积神经网络预测优于影像组学,B型超声AUC 0.72 vs 0.69、剪切波弹性成像AUC 0.80 vs 0.77(P=0.003)。
- 双模态超声联合分子数据的卷积神经网络模型准确率83.60%±2.63%。
核心结论
- 基于双模态超声与分子数据的治疗前卷积神经网络模型预测乳腺癌化疗反应表现优异,有望作为无创客观生物标志物辅助个体化治疗。
研究设计与样本
- 前瞻性研究,纳入2016年9月至2021年12月接受新辅助化疗的255例乳腺癌患者,基于治疗前B型超声和剪切波弹性成像图像,采用支持向量机分类器构建影像组学模型、ResNet架构构建卷积神经网络模型,最终模型联合双模态超声与独立相关的临床病理特征,采用五折交叉验证评估。
诊断标准与关键数值
- 剪切波弹性成像预测新辅助化疗反应优于B型超声(P<0.001);卷积神经网络优于影像组学,B型超声AUC 0.72 vs 0.69、剪切波弹性成像AUC 0.80 vs 0.77(P=0.003);双模态超声联合分子数据的卷积神经网络模型准确率83.60%±2.63%、敏感度87.76%±6.44%、特异度77.45%±4.38%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To carry out radiomics analysis/deep convolutional neural network (CNN) based on B-mode ultrasound (BUS) and shear wave elastography (SWE) to predict response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
MATERIALS AND METHODS: In this prospective study, 255 breast cancer patients who received NAC between September 2016 and December 2021 were included. Radiomics models were designed using a support vector machine classifier based on US images obtained before treatment, including BUS and SWE. And CNN models also were developed using ResNet architecture. The final predictive model was developed by combining the dual-modal US and independently associated clinicopathologic characteristics. The predictive performances of the models were assessed with five-fold cross-validation.
RESULTS: Pretreatment SWE performed better than BUS in predicting the response to NAC for breast cancer for both the CNN and radiomics models (P < 0.001). The predictive results of the CNN models were significantly better than the radiomics models, with AUCs of 0.72 versus 0.69 for BUS and 0.80 versus 0.77 for SWE, respectively (P = 0.003). The CNN model based on the dual-modal US and molecular data exhibited outstanding performance in predicting NAC response, with an accuracy of 83.60% ± 2.63%, a sensitivity of 87.76% ± 6.44%, and a specificity of 77.45% ± 4.38%.
CONCLUSION: The pretreatment CNN model based on the dual-modal US and molecular data achieved excellent performance for predicting the response to chemotherapy in breast cancer. Therefore, this model has the potential to serve as a non-invasive objective biomarker to predict NAC response and aid clinicians with individual treatments.
引用
- Huang, Shi, Ding, et al. Deep Learning Model Based on Dual-Modal Ultrasound and Molecular Data for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer. Acad Radiol. 2023. PMID: 37270368. doi:10.1016/j.acra.2023.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。